Analysis of the patient population included in NET trials nevertheless suggests that postmenopausal women with highly ER-positive (Allred score 6-8)/HER2-negative breast cancer that is too large for BCS or inoperable at diagnosis, are very good candidates for NET. Here, ERBB2 is linked to breast cancer.